VIVE — Vivesto AB Share News
0.000.00%
Last trade - 00:00- SEK95.10m
- SEK63.62m
Brief: Preliminary Result Of Oasmia's Rights Issue
Brief: Oasmia Signs Manufacturing Agreement With Lonza For Ovarian Cancer Drug Candidate Cantrixil
Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug
Brief: Oasmia Expands Research And Development Ability With Planned Laboratory Upgrade
Brief: Oasmia Expands Intellectual Property Portfolio In Key Territories
Brief: Oasmia Pharmaceutical Q4 Operating Loss Narrows To SEK 2.1 Mln
Brief: Oasmia Says Finds Novel Candidate For Use In XR-18 Platform
Brief: Oasmia Announces Intention To Change Name To Vivesto
Brief: Oasmia Resolves On Fully Secured Rights Issue Of About SEK 151 Mln
Brief: Oasmia Q3 Operating Loss Narrows To SEK 29.6 Mln
Brief: Oasmia Announces Global Settlement
Brief: Oasmia Pharmaceutical Signs License Agreement With Farmamondo Group
Brief: Oasmia Pharmaceutical Q2 Operating Loss Narrows To TSEK 56,165
Brief: Oasmia Transfers Nordic Commercialization Rights For Apealea To Inceptua
Brief: Oasmia Q1 Operating Loss Narrows To SEK 40.8 Mln
Brief: Oasmia Pharmaceutical: Phase 1B Trial Of Docetaxel Micellar Is Granted Ethical Committee Approval
Brief: Oasmia Presents Cantrixil Final Phase I Data At The 2021 AACR Annual Meeting
Brief: Oasmia Wins Sole Rights To Record Patents In Its Own Name And Is Awarded Full Legal Costs
Brief: Oasmia: European Patent Office To Grant Xmena Patent